meRfi®-GM
The Digital Textbook on Gut Microbiota and Beyond
brca1 gene mutant
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
References (Sources)
- Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers
- Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
- Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers
- The poly(adp-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial